Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-02-23 Board/Management Inform…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) regarding a change in executive leadership at Lupin Limited. It specifically discloses that Dr. Fabrice Egros is assuming new responsibilities as President, Corporate Development & Growth Markets, replacing Alan Butcher. The document references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about material events including changes in management. The content focuses on leadership change and does not contain financial data, audit information, or other report types. The document length is 4281 characters, which is relatively short and consistent with a management change announcement. Therefore, the document fits best under the category of Board/Management Information (MANG).
2022-02-23 English
Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets.
Regulatory Filings
2022-02-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Lupin Limited announcing the U.S. FDA approval of a supplemental New Drug Application (sNDA) for their product SOLOSEC. This is a standard corporate regulatory announcement regarding product development and regulatory status, which falls under the 'Regulatory Filings' category as it does not fit into specific financial report or governance categories.
2022-02-17 English
Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis.
Regulatory Filings
2022-02-17 English
Intimation regarding issuance of duplicate share certificate.
Regulatory Filings
2022-02-15 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015. It details the issuance of duplicate share certificates in lieu of lost certificates. The document is addressed to the stock exchange and signed by the company secretary. It is a regulatory compliance filing related to share certificates, not a financial report, earnings release, or management information. The document length is short (1914 characters) and it serves as a formal notification to the exchange. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-02-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.